[EN] APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'APELINE (APJ) ET LEURS UTILISATIONS
申请人:RES TRIANGLE INST
公开号:WO2015188073A1
公开(公告)日:2015-12-10
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
这项披露涉及到apelin受体(APJ)的激动剂以及这些激动剂的用途。
Thiazolyl-Dihydro-Indazoles
申请人:McCONNELL Darryl
公开号:US20120108567A1
公开(公告)日:2012-05-03
The present invention encompasses compounds of general formula (1)
wherein
R
1
to R
3
are defined as in claim
1
, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
本披露涉及到apelin受体(APJ)激动剂及其使用。
Apelin receptor (APJ) agonists and uses thereof
申请人:Research Triangle Institute
公开号:US10377718B2
公开(公告)日:2019-08-13
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
本公开内容涉及阿佩林受体(APJ)的激动剂及其用途。
Aza-Peptide Analogs as Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors with Oral Bioavailability
作者:Alexander Fässler、Guido Bold、Hans-Georg Capraro、Robert Cozens、Jürgen Mestan、Bernard Poncioni、Johannes Rösel、Marina Tintelnot-Blomley、Marc Lang
DOI:10.1021/jm960022p
日期:1996.1.1
A series of aza-peptide analogs with a (hydroxyethyl)hydrazine isostere has been synthesized as HIV-1 protease inhibitors using a simple synthetic scheme. Structure-activity studies based on the X-ray of a previously described inhibitor-enzyme complex led to potent inhibitors with antiviral activity in the low-nanomolar range. The S-configuration of the transition-state hydroxyl group was preferred in this series. Small modifications of the P2P3 and P-2'P-3' substituents had little effect on enzyme inhibition but greatly influenced the pharmacokinetic profile. As a result of these studies, the symmetrically acylated compound 8a and its close analog 24a bearing a methyl carbamate in P-3 and an ethyl carbamate in P-3' position were identified as potent inhibitors with plasma concentrations exceeding antiviral ED(50) values 150-fold following oral application in mice.